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The new coronavirus (COVID-19) was first detected in the city of Wuhan in China in December 
2019. Most patients infected with COVID-19 had clinical manifestations of dry cough, fever, short-
ness of breath, chest pain, fatigue and malaise, pneumonia, and bilateral chest CT infiltration. Soon 
COVID-19 spread around the world and turned into a pandemic. Now this disease affects many 
patients around the world. Patients with concomitant diseases have a high risk of COVID-19 infec-
tion, the infection is quite severe, leading to organ dysfunction, which is acute respiratory distress 
syndrome, acute kidney damage, septic shock, pneumonia and death. Currently, the coronavirus dis-
ease (COVID-19) is an imminent threat to global public health. Experts around the world are now 
actively searching for medicines that can stop the infection. Despite the fact that some modern ther-
apeutic drugs have demonstrated quite high capabilities in the field of prevention or treatment of 
patients with COVID-19, various side effects have occurred during their use. Therefore, a compre-
hensive assessment of the safety profile of therapeutic agents against COVID-19 is highly relevant. 
     




El nuevo coronavirus (COVID-19) se detectó por primera vez en la ciudad de Wuhan en China en 
diciembre de 2019. La mayoría de los pacientes infectados con COVID-19 tenían manifestaciones 
clínicas de tos seca, fiebre, dificultad para respirar, dolor en el pecho, fatiga y malestar, neumonía e 
infiltración bilateral de TC de tórax. Pronto, COVID-19 se extendió por todo el mundo y se convirtió 
en una pandemia. Ahora bien, esta enfermedad afecta a muchos pacientes en todo el mundo. Los 
pacientes con enfermedades concomitantes tienen un alto riesgo de infección por COVID-19, la 
infección es bastante grave y conduce a una disfunción orgánica, que es síndrome de dificultad res-
piratoria aguda, daño renal agudo, shock séptico, neumonía y muerte. Actualmente, la enfermedad 
por coronavirus (COVID-19) es una amenaza inminente para la salud pública mundial. Los expertos 
de todo el mundo están buscando activamente medicamentos que puedan detener la infección. A 
pesar de que algunos fármacos terapéuticos modernos han demostrado capacidades bastante eleva-
das en el campo de la prevención o el tratamiento de pacientes con COVID-19, se han producido 
varios efectos secundarios durante su uso. Por lo tanto, una evaluación integral del perfil de seguri-
dad de los agentes terapéuticos frente al COVID-19 es muy relevante. 
 





Coronaviruses are membranous, unsegmented, and single-stranded RNA viruses with a positive 
meaning. The starting point for the spread of this disease should be considered the end of December 
2019, when new cases of pneumonia caused by this virus were first detected in the Chinese city of 
Wuhan. The most common clinical signs and symptoms in the first and subsequent patients were 
dry cough, fever, shortness of breath, and bilateral chest CT infiltration. The causative agent of the 
new coronavirus was first detected using swobs taken from these patients. 
 
This new coronavirus was later named the severe acute respiratory syndrome coronavirus 
(SARS-CoV-2). Soon this disease was named (COVID-19), and its spread became pandemic. 
 
Most patients infected with COVID-19 have an average age of 50 years, most often the virus 
affects men. Approximately 25% of infected patients with severe forms of the disease are treated in 
hospitals, while 10% of these patients require artificial lung ventilation.  
 
Studies of European specialists in Italy showed that COVID-19 prevailed in men (59.8% in 
men and 40.2% in women), the majority of patients (about 75%) were over 50 years old, approxi-
mately 46% of all patients had a mild form of the disease, 25% showed a severe course of the disease, 
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5% were in a critical situation, and the remaining patients had minor symptoms, unspecified symp-
toms, or completely absent symptoms (Huang et al., 2020). 
 
According to recently published studies, the most common clinical manifestations in pa-
tients with COVID-19 were fever in 83-98% of patients, dry cough in 76-82%, and fatigue or myal-
gia in 11-44% of them. Other signs and symptoms reported include sore throat, headache, confusion, 
rhinorrhea, sneezing, ageusia, anosmia, chest pain, hypoxemia, pneumonia, hemoptysis, acute heart 
failure, neurological complications, and gastrointestinal symptoms such as nausea, vomiting, diar-
rhea, and abdominal pain. 
 
Patients with concomitant diseases are very likely to develop severe infection, which is ex-
pressed through acute respiratory distress syndrome, acute kidney injury, septic shock, etc. A severe 
form of COVID-19 can lead to death due to severe alveolar damage and highly progressive respira-
tory failure. 
 
CAVID-19 particles can be spread through the airway mucosa and through the fecal-oral 
route. The virus's nucleic acid was found in excrement samples and saliva. This virus can be trans-
mitted from person to person, and this form of transmission can significantly accelerate the spread 
of this virus.  
 
 Studies have shown that COVID-19 can also be transmitted by an asymptomatic carrier 
with an incubation period of 1 to 19 days. To prevent the spread of this new virus, hands should be 
washed frequently, you should not touch your face with unwashed hands, regular disinfection of 
surfaces is required, social distancing from people with respiratory symptoms is necessary, and other 
precautions are taken. 
 
Covid-19 diagnostics is also a special feature. According to published reports, in most pa-
tients with COVID-19, the absolute value of lymphocytes was reduced, indicating that this new 
coronavirus (COVID-19) acts more on lymphocytes, especially on T-lymphocytes, like the SARS 
coronavirus. 
 
COVID-19 can cause a cytokine storm and activate immune responses, which can manifest 
in changes in the number of white blood cells and immune cells, especially lymphocytes. The clinical 
outcome of such events will be respiratory distress syndrome, septic shock, and finally, damage to 
the target organ. COVID-19 can also affect the liver, resulting in hypoproteinemia, increased ami-
notransferases, and prolonged prothrombin time. Hepatotoxicity can be explained by higher expres-
sion of angiotensin converting enzyme II (ACE2) in cholangiocytes, ACE2 can act as an input re-
ceptor for COVID-19. It is also assumed that this new virus can directly damage the intrahepatic 
bile ducts. 
 
Pathological results of a liver biopsy of a patient with COVID-19 showed moderate mi-
crovesicular steatosis, as well as moderate portal and lobular activity, which may be the result of 
direct liver damage from SARS-CoV-2 or hepatotoxicity caused by antiviral drugs. 
 
Almost all patients with COVID-19 were diagnosed with abnormal lung CT. The analysis 
of studies showed that on average, patients with the considered diagnosis had 10.5 ± 6.4 segments, 
and the number of affected lung segments was significantly higher in the group of patients with 
symptoms compared to asymptomatic carriers of the disease (Zang et al., 2020). 
 
CT results showed that patients with COVID-19 may have both bilateral lung damage and 
peripheral or diffuse lung damage. The most common manifestations of chest CT were matte glass 
pattern, compaction, and fuzzy borders (Xia et al., 2020). 
 
According to WHO-approved laboratory PCR tests for the diagnosis of COVID-19, the di-
agnosis is based on a nucleic acid amplification test (NAAT), such as rRT-PCR, which can detect 
COVID-19 RNA sequence. 
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Materials and Methods 
 
During the preparation of the work, we analyzed studies related to the use of non-specialized medi-
cines for the treatment of a new coronavirus infection, as well as drugs developed directly for the 





As already noted, today medical specialists around the world are trying to find the most effective 
medicine against coronavirus infection. One of the directions in this area was the re-profiling of 
existing medicines. 
 
The medicine repurposing approach speeds up the drug discovery process and attracts the 
attention of researchers in a wide variety of fields of science (Zhou et al., 2020). Due to the availa-
bility of in vitro and in vivo screening data, complete chemical optimization, toxicity studies, mass 
production, formulation development, and pharmacokinetic profiles approved by the FDA, the med-
icine development cycles for coronavirus infection are shortened in this case, since all these critical 
steps can be bypassed. In addition, there is no need for larger investments, and the safety of repur-
posed medicines has been proven in preclinical models. Consequently, the main advantages of drug 
of adaptive reuse are associated with the established safety of known candidate compounds, a sig-
nificant reduction in the development time and costs associated with the promotion of a particular 
drug for clinical trials (Ruan et al., 2020). 
 
Most of the repurposed drugs were discovered by accident. In addition to random observa-
tions, drug repurposing can be performed using several strategies, including binding assays, pheno-
typic screening methods, and so on. In (Ruan et al., 2020), a brief overview of various approaches 
to medicine repurposing was presented.  
 
Table 1. Different approaches to re-purposing drugs for the treatment of COVID-19 
Name of approach Description 
Binding assay Identification of binding interactions of ligands with anal-
ysis components 
Phenotypic screening Evaluates a large number of approved or developed medi-
cations in various predictive models 
Evaluation of a number of connections in an array of in-
dependent models 
Targeted approach Identifying new indications on the basis of target proteins 
of the medicine 
Scientific approach Combines known information about the medicine with 
the prediction of unexplored biomarkers. 
Comparative approach Based on comparing the unique characteristics or "signa-
ture" of a medicine with the characteristics of another 
medicine, disease, or clinical phenotype 
 
Choosing the right approach is a crucial step in repurposing medicines. The possibilities for 
repurposing drugs are diverse, but much remains to be done to explore them. 
 
Within the framework of the above approaches, various strategies for repurposing medicines 
are used to determine the effectiveness of known drugs in respiratory viral infectious diseases using 
both screening of collections of bioactive small molecules and computational methods. The main 
non-core drugs studied by various specialists for use against COVIND-19 are presented in table 2. 
 
Table 2. Repurposed drugs in clinical development against various indications caused by respira-
tory viruses 
Medicine / composition Original designation A new use for respiratory viral 
infections 
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Sarilumab Rheumatoid arthritis COVID-19 
Favipiravir Flu COVID-19 
Ramdevpir A wide range of antiviral 
drugs 
COVID-19 
Danoprevir / ritonavir Danoprevir for hepatitis C COVID-19 
Dexamethasone Ritonavir for HIV COVID-19-associated acute res-
piratory distress syndrome 
Ivermectin / doxycycline Immunosuppressant COVID-19 
ASC09 / ritonavir Ivermectin for parasitic 
infections 
COVID-19 
Hydroxychloroquine Doxycycline for bacterial 
infections 
COVID-19 
Methylprednisolone Ritonavir for HIV COVID-19 
Tocilizumab Malaria COVID-19 
 
If an antiviral medicine has the ability to affect a specific pathway used for virus replication 
and is active against other viruses, it may be useful against COVID-19 (Ragab et al., 2020). 
  
Remdesivir, a broad-spectrum antiviral drug under investigation, has shown promising effi-
cacy in the treatment of MERS and SARS. Several recent studies have reported the effectiveness of 
remdesivir in the treatment of COVID-19 (Ragab et al., 2020). Similarly, chloroquine (approved for 
the treatment of malaria) has shown potential for reuse against influenza (Ye et al., 2020), MERS 
(suppression of virus replication), SARS, and COVID-19 (Ye et al., 2020). 
 
In addition, hydroxychloroquine (HCQ) has shown positive effects in the treatment of 
COVID-19, as reported in several recent studies (Ye et al., 2020). on March 28, 2020, the food and 
drug administration (FDA) issued an emergency use allowance (EUA) for the use of chloroquine 
phosphate and hydroxychloroquine sulfate for the treatment of COVID-19 (Xu et al., 2020). In ad-
dition, on May 1, 2020, the FDA granted permission for the use of remdesivir in emergency cases 
(EUA) for the treatment of COVID-19. However, June 15, 2020 The FDA has withdrawn EUA for 
emergency use of the oral formulations chloroquine phosphate and hydroxychloroquine sulfate 
based on current EUA analysis and new scientific data (Xu et al., 2020). 
 
Researcher L. Heimfarthab and her co-authors also studied many classes of drugs to mini-
mize the effects of COVID-19 (Heimfarth et al., 2020). They suggested that some of these drugs, 
such as chloroquine (CQ) and hydroxychloroquine (HCQ), had caused unnecessary insanity due to 
their indiscriminate use as preventive measures in a number of countries, including Brazil and the 
United States. 
 
Although this is not the main goal of most drugs currently used to treat COVID-19, there is 
growing evidence that the "cytokine storm" can have a significant impact on the development of the 
disease, especially in patients in critical condition (Heimfarth et al., 2020). However, there is no 
information on how these drugs can help control important cytokines and promote patient recovery. 
 
Some drugs that have been studied for their potential usefulness in COVID-19 have an anti-
inflammatory profile in other diseases and are being tested against hyperinflammation caused by 
SAR-COV-2 infection. 
 
Knowledge of the molecular targets of drugs in SAR-COV-2 infection and their subsequent 
effects on immune responses can help pave the way for empirical approaches and trials at this stage. 
The above authors presented a classification of drugs proposed for the treatment of COVID-19 that 
can modulate the observed inflammatory process. The classification includes antiviral, anti-rheu-
matic, anti-inflammatory, antitumor and antiparasitic drugs (table 3). It was noted that all these clas-
ses of drugs have a beneficial effect on patients with COVID-19 (Heimfarth et al., 2020). 
 
Table 3. Drugs used in the treatment of COVID-19 
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Class Drug, remedy, 
medicine 







Antiviral drugs for the treatment of COVID-19 and affected cytokines 
































































It is a prote-
ase inhibitor 







Ribavirin Antiviral drug Stops the synthe-







tion of RNA 
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Umifenovir Antiviral drug Inhibition of fu-
sion of the viral 
envelope and cy-
toplasmic mem-
brane of the host 
cell. 
It blocks the 
trimeriza-
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ACEi and ARB drugs for the treatment of COVIND-19 and the cytokines they affect 








and ACE 2, 
affecting the 
internaliza-
tion of the 
virus. 
















Ibrutinib Anticancer drug Covalent 
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Antibiotic Azithromycin Antibiotic It binds with the 







Chloroquine Antimalarial drug Immunosuppressi
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It changes 





















































It increases the 
production of in-
terferon alpha and 
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Research by medical specialists from China on the choice and effectiveness of medicines 
for the treatment of patients with a new coronavirus infection is also interesting. In China, the prac-
tice of fighting SARS-CoV-2 over the past four months has fully confirmed that traditional Chinese 
medicine plays an important role in the prevention and treatment of COVID-19 before the successful 
development of specific medicines and vaccines. Combined methods of treatment of traditional Chi-
nese medicine and chemical preparations increased clinical effectiveness, reduced the length of hos-
pital stay, and reduced the critical mortality rate (Pan et al., 2020). Therefore, these drugs, including 
recipes for Chinese herbal compounds, injectable drugs, and natural active ingredients with specific 
effects for the prevention and treatment of COVID-19, should be generalized and distributed. Pre-
scriptions for Chinese herbal compounds and injectable medications that have tried to prevent and 
treat COVID-19 in China are listed in table 4 (Pan et al., 2020). 
 
Table 4. Traditional Chinese medicine medications that can potentially be used for the prevention 




Compositions Indications Adverse reaction 












13 types of herbs: Po-
gostemonis 
Herba , Perillae Fo-
lium , Angelicae da-
huricae Radix , At-
ractylodis macroceph-
alae Rhizoma , Citri 
reticulatae Pericar-
pium , Pinelliae Rhi-
zoma Praepara-
tum , Magnoliae of-
ficinalis Cor-








Some people may 







An oral solution of wa-
ter or HuoxiangZhengqi 
solution is 5-10 ml once 
- twice a day. Tablets of 
2.5-5 g: once-2 times a 
day. Capsules are 4 cap-
sules once or twice a 
day. The diet should be 






Flos , Fritillariae 
thunbergii Bul-
bus , Scutellariae Ra-
dix , Arctii Fruc-
tus , Artemisiae an-
nuae Herba and oth-
ers. 
Various flu ： 
flu a (H1N1) 
Uncertain 
Take one sachet with 
boiled water twice a day 
for 3-5 days or as pre-
scribed by your doctor. 






13 types of 
herbs: Forsythiae 
Fructus , Lonicerae 
japonicae 
Flos , Ephedrae 
Herba , Armeniacae 
semen Ama-
rum , Gypsum Fibro-
sum , Isatidis Ra-
dix , Dryopteridis 
crassirhizomatis Rhi-
zoma , Houttuyniae 
Herba , Pogostemonis 
Herba and others. 
Flu 
It usually occurs af-
ter the first dose of 
medication, such as 
nausea, vomiting, 
bloating, diarrhea, 
rash, itching, etc. 
Oral administration of 4 
capsules or one granule 
at a time, three times a 
day. 7-10 days as a 
course for the mild and 
common form of 
COVID-19 
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Radix , Forsythiae 
Fructus , Isatidis 
Radix , Bupleuri 
Radix , Patriniae 
Herba , Verbenae 
Herba , Phragmitis 
Rhizoma , Glycyrrhiz






ache, high blood 
pressure, etc. 
Oral administration of 4 






17 types of 
herbs: Saposhnikov-
iae Radix , Schi-
zonepetae 
Spica , Menthae hap-
localycis 
Herba , Ephedrae 
Herba , Rhei Radix et 
Rhizoma , Natrii Sul-
fas , Gardeniae Fruc-






Oral administration, one 






nia #1 on 
prescrip-
tion) 
16 types of 
herbs: Scutellariae 
Radix , Forsythiae 
Fructus , Lonicerae 
japonicae Flos , Isa-
tidis Foliu and others 
Antivirus Uncertain 
Oral administration, 2 
sachets at a time, each 




21 types of 
herbs: Ephedrae 
Herba , Armeniacae 
semen Ama-
rum , Gypsum Fibro-
sum , Asari Radix et 
Rhizoma , Bupleuri 
Radix , Scutellariae 
Radix , Citri reticula-




It may occur after in-
appropriate medica-






One dose a day, once in 
the morning and even-
ing (in 40 minutes after 
meals), take with warm 
water, three times by a 
course. If possible, add 
half a cup of rice soup 




14 types of 
herbs: Ephedrae 
Herba , Pogostemonis 
Herba , Gypsum Fi-
brosum , Armeniacae 
semen Amarum , Pi-
nelliae Rhizoma Prae-
paratum , Rhei Radix 
et Rhizoma , Glycyr-
rhizae Radix et Rhi-
zoma and others. 
Pneumonia Uncertain 
1-2 doses per day, de-
coction, 100-200 ml 
each time, 2-4 times a 





13 types of 
herbs: Ephedrae 
Herba , Armeniacae 
semen Ama-
rum , Gypsum Fibro-







One dose per day, 400 
ml decoction, take 200 
ml in the morning and 
evening, respectively. 
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Herba , Artemisiae 
annuae 
Herba , Glycyrrhizae 
Radix et Rhi-







fection of the 
upper respira-
tory tract, viral 
bacterial pneu-
monia, influ-




such as nausea and 
vomiting. 
Viral infection or com-
bined mild bacterial in-
fection: 0.9% sodium 
chloride injection 250 
ml + Ciyanping injec-




Carthami Flos , Paeo-
niae Radix Ru-
bra , Chuanxiong 
Rhizoma , Salviae 
miltiorrhizae Radix et 
Rhizoma and Angeli-
cae sinensis Radix 
Lung infection 








tional organ failure: 
0.9% sodium chloride 
injection 250 ml + 
xuebijing injection 100 
ml - 2 times a day. 
Shen fu 
injection 
Radix et Rhizoma ru-
bra ginseng and aco-






Shock: injection of 0.9% 
sodium chloride - 250 
ml + injection of 100 ml 
Shenfu 2 times a day. 
Shengmai 
injection 
Ginseng Radix et 
Rhizoma ru-










Allergic rash, back 
pain 
Immunosuppression: 
glucose injection 250 ml 
+ Shengmai injection 




Herba , Lonicerae ja-








ness, dry mouth, di-
arrhea, nausea, and 
vomiting. Occasional 
allergic reactions, 
such as redness, itch-
ing, or a rash all over 
the body. 
Viral infection or com-
bined mild bacterial in-
fection: injection of 
0.9% sodium chloride 
250 ml + repeated injec-






dix , Pulvis fetis 
Ursi , Goat horn , Lo-
nicerae japonicae 







tic shock, dizziness, 
nausea, vomiting, 
itching, rash, high fe-
ver, heart and kidney 
function disorders, 
etc. 
Viral infection or com-
bined mild bacterial in-
fection: 0.9% sodium 
chloride solution for in-
jection 250 ml + 
Tanrecin injection 40 ml 




Moschus , Gardeniae 
Fructus , Curcumae 







itching, rash, and fe-
ver. Sometimes there 
are adverse symp-
toms such as tight-
ness in the chest, 
belching, rapid 
High fever with im-
paired consciousness: 
0.9% sodium chloride 
solution for injection 
250 ml + injection Xing-
naojing 20 ml 2 times a 
day. 
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Ginseng Radix et 
Rhizoma ru-










reactions, such as 
palpitations, short-
ness of breath, tight-
ness in the chest, red-
ness of the face, etc. 
Sometimes 
anaphylactic shock, 
shortness of breath, 
and heart failure. 
Immunosuppression: 
250 ml glucose injection 
+ 100 ml Shenmai injec-
tion twice a day 
 
However, the authors point out that the clinical use of the above-mentioned medicines of 





Next, we think, it necessary to consider the effectiveness and results of clinical trials of some of the 
drugs presented above. 1. Lopinavir / ritonavir. Initially, this drug was mainly used for the treatment 
of human immunodeficiency virus (HIV) infection in adults and children over 2 years of age. In 
vitro studies have shown that lopinavir and ritonavir can reduce SARS-CoV and MERS-CoV levels 
(Li et al., 2020). Based on the results of significant clinical benefits of lopinavir and ritonavir in 
patients with SARS-CoV infection, scientists have suggested that this drug may be effective in pa-
tients with SARS-CoV-2 infection (Li et al., 2020). The team from Zhongshan University built a 
structural model of two new coronavirus proteases-coronavirus endopeptidase C30 and papain-like 
protein using homology modeling and docked lopinavir / ritonavir with protease models, respec-
tively. The results showed that lopinavir and ritonavir are more easily combined with coronavirus 
endopeptidase C30 compared to pa-pain-like enzymes that exhibit excellent effects against SARS-
CoV-2 (Coperchini et al., 2020). However, after using lopinavir / ritonavir tablets, 40 patients diag-
nosed with COVID-19 in 29 cases experienced adverse reactions associated with lopinavir / ri-
tonavir, such as increased triglyceride levels, nausea, and diarrhea (Russell et al., 2020). Therefore, 
larger clinical trials of this drug should focus on its safety. 
 
2. Ribavirin. It is a broad-spectrum antiviral drug that can be phosphorylated in red blood 
cells to form ribavirin monophosphate, diphosphate, and triphosphate. Ribavirin monophosphate is 
a strong inhibitor of inosinemonophosphatedehydrogenase, which can inhibit the synthesis of 
guanylatephosphate in cells, reduce the level of guanylate triphosphate in cells, and block the syn-
thesis of viral nucleic acids. Ribavirin triphosphate inhibits influenza virus RNA-polymerase, 
thereby preventing virus replication (Zhang et al., 2020). Ribavirin has been shown to inhibit SARS-
CoV replication in five different cell types obtained from animals or humans in therapeutically 
achievable concentrations (Zhang et al., 2020). However, when using ribavirin, some side effects 
should be noted. For example, 61% of patients developed hemolytic anemia, 58% hypocalcemia, 
and 46% hypomagnesemia in 110 SARS patients treated with ribavirin [14]. Taking into account the 
effectiveness of ribavirin in the treatment of diseases caused by SARS-CoV and MERS-CoV, it is 
expected to be an effective drug for the treatment of COVID-19. However, the effectiveness of rib-
avirin for the treatment of COVID-19 is still controversial, which are needed for further confirmation 
in clinical trials.  
 
3. Chloroquine. Chloroquine is an anti-malarial and anti-inflammatory agent that has been 
widely used in the treatment of malaria and rheumatoid arthritis for more than 70 years. The anti-
malarial effect of chloroquine can interfere with replication and transcription of Plasmodium schi-
zonta DNA or interfere with its endocytosis, which leads to the death of the parasite due to amino 
acid deficiency. Chloroquine also has an immunomodulatory activity that can synergistically en-
hance antiviral effects (McGonagle et al., 2020). Several consecutive clinical trials have now been 
announced. The results of an open non-randomized clinical study showed that hydroxychloroquine 
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is significantly associated with a decrease or disappearance of the viral load in patients with COVID-
19 (Ulhaq, 2020). Similarly, another randomized clinical trial also confirmed the effectiveness of 
hydroxychloroquine against COVID-19, which is shown to reduce the recovery time of body tem-
perature and the time of remission from cough in patients with COVID-19 (Ulhaq, 2020). 
 
Preliminary data from a multicenter prospective observational study showed that the average 
time to undetectable viral RNA was shorter for chloroquine than for non-chloroquine, and no serious 
adverse reactions were observed in the chloroquine group (Levi et al., 2020). In contrast, the results 
of some clinical studies have shown negative results of treatment WITH covid-19 with chloroquine 
or hydroxychloroquine. For example, an open randomized controlled trial showed that hydroxychlo-
roquine did not lead to a higher probability of negative conversion than applying a single standard 
of treatment in patients with mild to moderate COVID-19, and side effects, especially diarrhea, were 
higher after taking hydroxychloroquine (Zhang et al., 2020).  
 
4. Arbidol. Arbidol inhibits the fusion between the viral envelope and the cell membrane of 
target cells, thereby preventing the virus from entering target cells (Snijder et al., 2006). Arbidol is 
often used to counter flu viruses in Russia and China, which is not yet approved for sale in other 
countries. In vitro and in vivo studies have shown that Arbidol has antiviral activity against influenza 
virus, RSV, rhinovirus, Coxsackie virus, Coxsackie B5 virus, and adenovirus (Snijder et al., 2006). 
 
Previous research has shown that Arbidol can inhibit RNA viruses and filoviruses such as 
SARS-CoV and MERS-CoV. Chinese scientists have found that Arbidol can effectively suppress 
the pathological effects of SARS-CoV-2 at a concentration of 10 ~ 30 µmol / l with a 60-fold viral 
load in vitro by screening various antiviral drugs. Currently, two RCCT have been initiated to eval-
uate the efficacy and safety of Arbidol in the treatment of COVID-19 in China. 
 
5. Favipiravir. Favipiravir is a viral RNA polymerase inhibitor that action can be mediated 
by its metabolite ribofuranosyl-5' - triphosphate (RTP), which inhibits the activity of influenza virus 
RNA polymerase. Favipiravir was urgently used, which demonstrated a good inhibitory effect on 
the Ebola virus in 2014 (Senanayake, 2020). Despite its relatively modest antiviral activity, favipi-
ravir can completely inhibit the replication of mouse norovirus (MNV) at a concentration of 100 
micrograms / ml with or without minor side effects on cells (cell survival> 80%) [20]. Favipiravir 
was officially approved by the Chinese medical products administration for marketing and officially 
launched into production in China. Favipiravir is the first approved drug with a potential therapeutic 
effect for COVID-19 in China, which will play an important role in the prevention and control of 
SARS-CoV-2 infection (Senanayake, 2020). 
 
6. Remdesivir. It has a strong antiphilovirus effect in vitro and a certain anti-coronavirus 
effect due to the inhibition of RNA-dependent RNA synthetase in experiments on animals. Subse-
quent studies have shown that remdesivir is not only effective against Ebola virus, but also sup-
presses respiratory syncytial virus, coronavirus, Nipah virus, and Hendra virus (Devaux et al., 2020). 
 
Researchers reported that the first patient with COVID-19 in the United States recovered 
after treatment with remesivir (Devaux et al., 2020). In November 2019, the results of a phase II 
clinical trial showed that 175 out of 681 Ebola patients were treated with remdesivir after 29 serious 
adverse reactions, only one of which was associated with remdesivir (Schlagenhauf et al., 2020). 
 
 Preliminary results of a clinical study conducted by the National Institute of Allergy and 
Infectious diseases (NIAID) in the United States showed that patients treated with remdesivir had a 
31% faster recovery time than patients treated with placebo, indicating a significant positive effect 
of remdesivir on reducing the recovery time of patients with COVID-19 (Schlagenhauf et al., 2020). 
However, a randomized double-blind placebo-controlled multicenter clinical trial conducted by Chi-
nese scientists showed that remdesivir does not accelerate recovery and does not reduce mortality in 
patients with severe COVID-19 compared to the placebo group. The rate of early discontinuation 
due to side effects, including nausea, vomiting, and cardiopulmonary failure, was higher in the 
remdesivir group than in the placebo group (11.6% vs. 5.1%). Although this is the first quality clin-
ical trial of remdesivir in the treatment of COVID-19, only 237 samples are included in the clinical 
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trial. Consequently, the antiviral efficacy and safety of remdesivir still need to be confirmed by 
higher-quality clinical trials with larger samples (Levi et al., 2020). 
 
7. Rapamycin. This drug is one of the new drugs offered for the treatment of COVID-19 
today is rapamycin (Kalra et al., 2020). It is a macrolide immunosuppressant that inhibits mTOR. 
MTOR is a serine / threonine protein kinase that exists in the form of two protein complexes 
(mTORC1 and mTORC2) with different protein components and substrates (Kalra et al., 2020).  
MTORC1 is sensitive to rapamycin, as well as to environmental stimuli including amino acids, glu-
cose, and oxygen, and is also known as a rapamycin-sensitive complex. MTORC2 acts below PI3K 
and is best described as an insulin / IGF-1 (insulin-like growth factor-1) signal effector (Husain & 
Byrareddy, 2020) and is known as a rapamycin-insensitive complex. MTORC1 controls protein syn-
thesis, autophagy, and many other cellular processes by phosphorylating the ribosomal protein S6, 
p70S6K, and 4E-BP1, whereas mTORC2 is necessary for maximum activation of many kinases, 
including AKT (protein kinase B) (Husain & Byrareddy, 2020). 
Target proteins, mTOR, and related rapamycin pathways are widely expressed in almost all 
eukaryotic organisms, and also regulate proliferation, transcription, autophagy, metabolism, and pro-
grammed cell death (Pandey et al., 2020). Based on scientific evidence and due to the involvement 
of mTOR in the regulation of pathways related to cellular metabolism, proliferation, aging, and im-
mune regulation, here we describe the potential for drug reprofiling that may allow us to consider 
rapamycin as a drug candidate for the treatment of COVID-19 (Liu et al., 2020). 
 
Traditional Chinese medicine products should also, in our opinion, receive more extensive 
study due to their ability to resist COVID-19. Chinese herbal recipes refer to a recipe consisting of 
two or more components for the treatment of a relatively specific disease and syndrome, which has 
a relatively prescribed treatment method and method of use. Each herb in the Chinese herbal com-
pound recipe has a specific medicinal effect that interacts with each other to enhance the therapeutic 
effect or reduce toxicity and side effects. Recipes of Chinese herbal mixtures are widely used in 
clinical practice, which in general has a complex effect on the broad-spectrum antibacterial, antiviral 




In a relatively short period of time, a significant amount of research has been conducted to 
better understand the structure of SARS-CoV-2 and the impact of this virus on human health in order 
to develop effective countermeasures. Using information about viral proteins, several research 
groups are developing vaccines and medicines. Some of these therapeutic and prophylactic drugs 
are currently undergoing clinical trials. It is expected that vaccines and medicines will be found that 
will reduce the global damage to public health caused by this virus (https://www.fda.gov). 
     China has some experience in the prevention and treatment of SARS-CoV-2 infection 
using the above-mentioned medicines, including chemicals, traditional Chinese medications and bi-
ological products. Although these drugs are expected to be specific medicines for the treatment of 
COVID-19, caution should be exercised when taking these drugs without sufficient evidence of their 
effectiveness and safety. These potential medications are currently being used to treat COVID-19 in 
many countries and regions due to the COVID-19 outbreak. The main characteristics of these drugs, 
including pharmacological effects, indications, and adverse reactions, and especially progress in the 
treatment of COVID-19, should be understood in order to promote reasonable medications and guide 
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